DDInter405 DDInter1676
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Clofarabine {u} (Compound) resembles {v} (Compound) Adenosine monophosphate
Clofarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Clofarabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Clofarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Clofarabine {u} (Compound) binds {v} (Gene) DCK
Clofarabine {u} (Compound) upregulates {v} (Gene) FAS
Clofarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Clofarabine {u} (Compound) downregulates {v} (Gene) ARL6IP1
Clofarabine {u} (Compound) causes {v} (Side Effect) Escherichia bacteraemia
Clofarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Clofarabine (Compound) resembles Adenosine monophosphate (Compound)
Clofarabine (Compound) resembles Nelarabine (Compound)
Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Clofarabine (Compound) treats hematologic cancer (Disease)
Clofarabine (Compound) binds DCK (Gene)
Clofarabine (Compound) upregulates FAS (Gene)
Clofarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Clofarabine (Compound) downregulates ARL6IP1 (Gene)
Clofarabine (Compound) causes Escherichia bacteraemia (Side Effect)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin